Aerovate Therapeutics (AVTE) Competitors $6.95 -0.19 (-2.66%) As of 09/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. FHTX, OCGN, SCPH, GLUE, CAPR, DRUG, MREO, ACB, ALEC, and ENGNShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Foghorn Therapeutics (FHTX), Ocugen (OCGN), scPharmaceuticals (SCPH), Monte Rosa Therapeutics (GLUE), Capricor Therapeutics (CAPR), Bright Minds Biosciences (DRUG), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Alector (ALEC), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Foghorn Therapeutics Ocugen scPharmaceuticals Monte Rosa Therapeutics Capricor Therapeutics Bright Minds Biosciences Mereo BioPharma Group Aurora Cannabis Alector enGene Aerovate Therapeutics (NASDAQ:AVTE) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Which has stronger valuation and earnings, AVTE or FHTX? Aerovate Therapeutics has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.09Foghorn Therapeutics$22.60M12.86-$86.62M-$1.19-4.32 Does the media favor AVTE or FHTX? In the previous week, Foghorn Therapeutics had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Foghorn Therapeutics and 0 mentions for Aerovate Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.86 beat Aerovate Therapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Foghorn Therapeutics Positive Is AVTE or FHTX more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -311.90%. Foghorn Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Foghorn Therapeutics -311.90%N/A -28.00% Do analysts recommend AVTE or FHTX? Foghorn Therapeutics has a consensus price target of $10.67, suggesting a potential upside of 107.52%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17 Do institutionals and insiders hold more shares of AVTE or FHTX? 61.6% of Foghorn Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, AVTE or FHTX? Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. SummaryFoghorn Therapeutics beats Aerovate Therapeutics on 12 of the 16 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.45M$857.31M$5.77B$10.28BDividend YieldN/A4.84%5.74%4.64%P/E Ratio-2.321.2076.8626.97Price / SalesN/A26.49544.13128.91Price / CashN/A19.5637.1760.63Price / Book1.766.7013.836.37Net Income-$75.52M-$4.03M$3.29B$271.46M7 Day Performance-10.44%-1.48%1.57%2.53%1 Month Performance-7.33%10.17%6.86%9.42%1 Year Performance-89.97%19.18%81.58%30.16% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$6.95-2.7%N/A-89.6%$201.45MN/A-2.3220High Trading VolumeFHTXFoghorn Therapeutics2.86 of 5 stars$5.33-7.3%$10.67+100.1%-46.2%$303.85M$22.60M-4.52120News CoverageAnalyst UpgradeGap UpOCGNOcugen1.8902 of 5 stars$1.04+0.5%$6.00+479.7%+25.0%$302.53M$4.05M-5.1780Positive NewsGap UpSCPHscPharmaceuticals4.4022 of 5 stars$5.62+0.7%$7.78+38.5%+3.5%$299.28M$36.33M-3.1030GLUEMonte Rosa Therapeutics2.7019 of 5 stars$4.85+0.9%$15.33+216.5%+16.5%$299.23M$75.62M13.4690Trending NewsAnalyst RevisionCAPRCapricor Therapeutics2.511 of 5 stars$6.44+1.4%$22.56+250.4%+25.0%$294.65M$13.39M-3.93101Analyst RevisionGap UpDRUGBright Minds Biosciences3.3097 of 5 stars$41.03-4.5%$81.00+97.4%+3,912.0%$287.51MN/A-43.91N/AAnalyst ForecastMREOMereo BioPharma Group1.7122 of 5 stars$1.81+0.8%$7.40+310.0%-58.1%$287.00M$10M-25.7940Gap UpACBAurora Cannabis0.4075 of 5 stars$5.07+4.7%N/A-11.5%$286.48M$246.72M-26.711,130News CoverageALECAlector3.9385 of 5 stars$2.81+1.6%$4.17+48.5%-44.5%$283.89M$100.56M-2.42270ENGNenGene2.8704 of 5 stars$5.52+1.6%$23.29+322.2%-4.3%$281.56MN/A-3.3431Earnings ReportAnalyst Revision Related Companies and Tools Related Companies Foghorn Therapeutics Competitors Ocugen Competitors scPharmaceuticals Competitors Monte Rosa Therapeutics Competitors Capricor Therapeutics Competitors Bright Minds Biosciences Competitors Mereo BioPharma Group Competitors Aurora Cannabis Competitors Alector Competitors enGene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts